Objective The aim of this study was to assess the actual effectiveness of long-term phlebotomy by comparing histological improvement (HI) in 69 Caucasian HCV-RNApositive CHC patients undergoing phlebotomy or receiving an interferon-based therapy without virological response [nonresponders to interferon therapy(IBT-NR)].
Introduction
Hepatitis C virus (HCV) infection represents a major cause of chronic hepatic inflammation worldwide [1] . In about 20% of these patients the disease evolves to liver cirrhosis and/or hepatocellular carcinoma [1] . Anti-HCV therapies based on the association of interferon and ribavirin are effective in about half of the treated patients by inducing sustained virological response [2, 3] . Nonetheless, there is an urgent need of other therapeutic options capable to prevent the progression of the disease for those patients who do not respond to the antiviral therapy.
The progression of chronic hepatitis C (CHC) is not linear and is greatly influenced by a variety of factors including male sex, age at the infection, obesity, coinfection with hepatitis B or HIV viruses, alcohol consumption, and iron overload [4, 5] . Mild hepatic iron accumulation is common in CHC patients and is associated with higher aminotransferase levels and more severe fibrosis [6, 7] .
In recent years, several groups have reported on the efficacy of iron reduction therapies based on phlebotomy in combination with or without an iron-poor diet in ameliorating aminotransferase levels in CHC patients who were nonresponders to the interferon treatment [8] [9] [10] [11] . Moreover, few reports have also addressed the long-term effects of phlebotomy showing its effectiveness in promoting CHC histological improvement (HI) [12, 13] . However, one bias of these latter studies is that improvements in liver histology may occur spontaneously during the natural history of CHC [14, 15] . In particular, the recent Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial has shown improvements in Ishak's fibrosis score in about 30% of untreated patients who were nonresponders to peginterferonribavirin therapy [15] . Iron depletion might be a simple and inexpensive treatment for those patients not responding to the antiviral therapy or having contraindications to its use. A previous study from our center [13] has addressed the role of phlebotomy in patients with CHC demonstrating that males with mild iron overload may have particular benefit from this procedure. Nonetheless, it is important to verify whether the HIs induced by phlebotomy effectively exceed those occurring spontaneously. To this aim, we have performed a case-control study comparing, retrospectively, the histological outcomes of a group of Caucasian CHC patients treated with long-term phlebotomy (LTP) with those of patients receiving an interferon-based therapy without virological response who underwent a second liver biopsy within 2-5 years from the diagnosis.
Materials and methods

Patient selection
The clinical and histological data of all consecutive HCV-RNA-positive Caucasian patients who underwent a second liver biopsy for CHC between 2000 and 2006 at two Italian centers (Ospedale Maggiore della Carità in Novara and Spedali Civili in Brescia) were reviewed. Criteria of exclusion from the study were HBs Ag and/or HIV-Ab positivity, personal or familial history of hemochromatosis, hemoglobin less than 13 g/dl for men and less than 11 g/dl for women at the time of their first liver biopsy, antiviral or immunosuppressive therapies during the 6 months that preceded the first liver biospy, active drug addiction, mean daily alcohol intake greater than 80 g/day (evaluated by trained medical staff according to a standardized questionnaire, presented as part of a survey on life habits), the presence of hepatocellular carcinoma at imaging studies, and the lack of a treatment (interferon-based or by phlebotomy) between the two liver biopsies. Tests for hemochromatosis gene mutations were not performed. However, the hepatic iron concentration (HIC) and iron index excluded phenotypic hemochromatosis in all the recruited patients.
The process identified 72 patients, of whom three were excluded because the first liver biopsy specimen was no longer available (one case) or was inadequate (two cases).
Among the 69 recruited patients (51 male and 18 female; mean age 53.1 ± 10.6), 30 patients (22 men, eight women; mean age 58.4 ± 8 years) who were either previously nonresponders (n = 14) or had contraindications to antiviral therapy (n = 16) were treated exclusively with iron reduction by phlebotomy between the two liver biopsies (group 1). These patients underwent an initial period of bimonthly or monthly phlebotomy of 250 ml of blood, until serum ferritin levels of 35 ng/ml or less were reached. Thereafter, maintenance phlebotomies were performed every 1 to 3 months during a minimum 2-year period to maintain a serum ferritin at 70 ng/ml or less. No sideeffects related to the mild iron depletion were reported. Phlebotomized patients underwent a second liver biopsy after 1442 ± 502 days. In these patients, who had given informed consent to be treated exclusively by phlebotomy, the second biopsy was performed as a part of a study approved by the local ethical committee to evaluate on an individual basis whether iron depletion by phlebotomy was effective and worthwhile to be continued.
The remaining 39 patients (29 male and 10 female; mean age 48.9 ± 10.5 years) showed a nonresponse to the antiviral treatment, which they had received after the first liver biopsy and underwent a second liver biopsy after 1963 ± 880 days, to decide whether antiviral treatment should be reoffered. These patients (group 2) had received antiviral therapy between the two liver biopsies, consisting of regular interferon a at standard doses and duration according to HCV genotype in 38 patients, 32 of whom were treated with monotherapy for either 24 weeks (12 cases) or 48 weeks (20 cases) and six with interferon a plus ribavirin. One patient was treated with peginterferon a and ribavirin at standard doses for 24 weeks. Of them, 32 were primary nonresponders, whereas the remainder experimented on a breakthrough after an initial virological response (three cases) or relapse after treatment (four cases). The demographic, clinical, and laboratory characteristics of the patients included in the study are summarized in Table 1 .
The study was planned according to the guidelines of the local ethical committee in conformity with the 1975 Declaration of Helsinki and all patients gave informed consent to retrospective data analysis.
Assessment of liver histology
Liver biopsies were performed using a modified Menghini procedure. Five-micron-thick sections were stained with haematoxylin/eosin, Masson's trichrome, and periodic acid-Schiff after diastase digestion as well as with the Gomori's method for reticulin and the Perls's method for iron staining. Only specimens with a minimum length of 15 mm and at least six portal tracts were considered adequate for histological assessment. Liver biopsy specimens were scored in a blind fashion by two expert pathologists (R.B., C.B.) unaware of the clinical data. In the case of discordant opinions, the two examiners analyzed together the discrepancies to reach a consensus.
The original histology activity index proposed by Knodell [16] was used for grading inflammation/necrosis and for staging fibrosis. By this scoring system inflammation/necrosis score ranges from 0 to 18 (0-10 periportal ± bridging necrosis, 0-4 intralobular degeneration and focal necrosis, 0-4 portal inflammation), whereas fibrosis stage only includes four steps: 0, no fibrosis; 1, fibrous portal expansion; 3, bridging fibrosis; 4, cirrhosis. Steatosis was scored semiquantitatively as: 0 = no steatosis, 1 = steatosis 33% or less of hepatocytes, 2 = steatosis in 34-66% of hepatocytes, 3 = steatosis in at least 66% of hepatocytes. Intrahepatic iron deposition was evaluated in specimens stained by the Perls' method and evaluated using the Searle's semiquantitative score [17] . As in previous studies, patients were defined as histologically improved when they showed at least one point reduction of staging score or, in the case of unchanged staging score, an at least two point reduction of the grading score [18, 19] .
Measurement of hepatic iron content
HIC was measured by atomic absorption spectroscopy on a portion of each liver biopsy, as previously reported [20] , and the values were expressed as mmol/g dry weight.
Normal cut-off values for HIC were taken at 25 mmol/g. Hepatic iron index was calculated to rule out phenotypic hemochromatosis.
Statistical analysis
Stata Statistical Software (release 10.0 College Station, Stata Corporation, Texas, USA) was used in all of the statistical analyses. Each variable predictive or associated with the presence of histological response was analyzed with univariate logistic regression. The variables selected by every univariate analysis were entered into logistic regression models with the use of a forward stepwise elimination algorithm (terms with P > 0.05 were eligible for removal). The characteristics of the patients at the time of their first liver biopsy, grouped by treatment, were compared with the two-sample t-test, the Fisher's exact test, or the Wilcoxon rank-sum test. Clinical and laboratory changes according to the treatment between the two liver biopsies were compared with the paired Student's t-test or the Wilcoxon matched-pairs signed- ranks test. A P value of less than 0.05 was considered as statistically significant.
Results
The epidemiological, clinical, and laboratory characteristics of the 69 patients included in the study, recorded at the time of their first liver biopsy, are summarized in Table 2 . The patients were grouped as receiving long-term phlebotomy (group 1) or interferon-based therapy (group 2). The patients receiving long-term phlebotomy were older and had higher serum ferritin, HIC, and hepatic iron grade at the time of their first liver biopsy than the nonresponders of the interferon-based therapy (IBT-NR) ( Table 2) . However, aminotransferase, g-Glutamyl transpeptidase serum levels, grading, and staging scores at the time of the first liver biopsy did not significantly differ between the two groups ( Table 2 ). The mean interval between the two liver biopsies was shorter in LTP patients (1442 ± 502 days) than in those treated with interferon-based therapy (1963 ± 880 days; P = 0.005).
At the time of the second liver biopsy AST (P < 0.001), ALT (P = 0.001), and GGT (P = 0.003) levels were significantly lowered only in the subjects receiving phlebotomy (Table 3) . Overall, ALT levels decreased in all 30 LTP patients, whereas AST and GGT levels were lowered in 28 of 30 (93%) and 23 of 30 (77%), respectively. Moreover, eight of the 30 (27%) phlebotomized patients achieved persistently normal aminotransferase levels during the iron-depleting treatment. As expected hemoglobin, transferrin saturation, serum iron, serum ferritin, hepatic iron grade, and the HIC were significantly decreased only in phlebotomized patients. On the contrary, hepatic iron grade was slightly increased at the time of the second liver biopsy in IBT-NR patients (Table 3) . During histological examination, it was found that the medians of the necroinflammatory grading and staging scores between the first and the second liver biopsy were not significantly different in the two groups (Table 3) . HI was defined by at least one-point reduction of staging score or, in case of unchanged staging score, by at least two-point reduction of grading score, according to the Knodell's Hepatic Activity Index. HI was observed in 15 of 30 (50%) patients receiving phlebotomy and in six of 39 (15%) IBT-NR subjects (P = 0.002). Among the 21 patients showing HI, 10 showed improvement of both the grading and the staging scores, 10 of the grading score only, and one of the staging score only.
The univariate and multivariate analyses showed that histological grading score at the time of the first liver biopsy [odds ratio (OR): 1.62; confidence interval (CI) 1.22-2.16; P = 0.001], and the treatment with LTP (OR: 10; CI 2.25-43.7; P = 0.002) were the only factors predictive for HI (Table 4) . These OR values were not substantially modified after correction for the difference in time laps between the two biopsies (histological grading at the first biopsy OR: 1.61; CI 1.23-2.19 and LTP OR: 10.8; CI 2.10-55.7).
Discussion
CHC patients unsuitable for antiviral treatments or not achieving sustained virological response to interferonribavirin therapy are at high risk for progression to cirrhosis, decompensated liver disease, and hepatocarcinoma [1, 5] .
Therefore, there is a high interest in developing alternative treatments that can attenuate the disease evolution. Mild iron accumulation is a common feature in liver biopsies from CHC patients and is associated with higher serum aminotransferase levels and worsening of liver fibrosis [6] . Consistently, several studies have demonstrated that lowering hepatic iron by phlebotomy alone or in combination with an iron-poor diet ameliorates serum aminotransferase levels in CHC patients who failed a sustained virological response by interferon-based treatments [8] [9] [10] [11] . Furthermore, we have reported that menstruating women experienced a milder CHC than men of the same age in relation to the lower HIC due to blood losses [21] . Although phlebotomy does not interfere with HCV RNA levels [22] , Yano et al. [12] have shown that in CHC patients nonresponders to interferon, a 5 year ironreducing treatment significantly lowers necroinflammatory grading and prevents the worsening of fibrosis in two sequential liver biopsies. In addition, Kato et al. [23] have reported that phlebotomy, in combination with an ironpoor diet, significantly reduces the development of hepatocarcinomas associated to CHC.
Our present study not only confirms the capacity of phlebotomy to decrease aminotransferase release in Caucasian CHC patients [22] , but also shows that 27% of the phlebotomized subjects achieve persistently normal aminotransferase levels during the iron-depleting treatment. Furthermore, half of our patients treated with phlebotomy alone showed hepatic histological improvement (as defined by one-point reduction of the individual staging score or, in the case of unchanged staging score, as a two-point reduction of grading score) after a mean period of 4 years since the beginning of treatment. Recent reports have shown that histological improvement occurs spontaneously in a variable proportion of CHC patients in whom antiviral therapy failed to eradicate the virus [14, 15] . Our data demonstrate that the frequency of histological improvements among phlebotomized patients is significantly higher (P = 0.002) than that occurring spontaneously in nonphlebotomized subjects. Furthermore, following the multivariate analysis phlebotomy results as a predictor of histological improvement in those patients. To our knowledge, this is the first attempt to evaluate the effectiveness of phlebotomy in CHC patients by a case-control analysis. However, we are well aware of the limitations of this study connected with its retrospective nature and the fact that most of the patients receiving the interferon-based therapy were recruited at the time when pegylated interferon and the combination therapy were not yet available.
So far the mechanisms responsible for the beneficial effects of phlebotomy in preventing the evolution of CHC have not been characterized in detail. Growing evidence indicates the oxidative stress as one of the mechanisms by which HCV causes hepatic injury [24] . In this context the capacity of the iron to exacerbate oxidative stress suggests that iron accumulation might amplify the processes leading to both hepatocellular damage and fibrosis [25] [26] [27] . Consistently, the measurement of 8-hydroxy-2 0 -deoxyguanosine, a well-recognized marker of oxidative stress, in liver biopsies from CHC patients is significantly associated with hepatic iron content and necroinflammation indices [28] . Moreover, iron depletion by phlebotomy greatly reduces the liver 8-hydroxy-2 0 -deoxyguanosine content in CHC patients [29] , suggesting that the efficacy of phlebotomy in preventing the CHC progression might relay on the reduction of oxidative damage promoted by the combination of HCV infection and iron accumulation.
In conclusion, our results indicate that in Caucasian CHC patients long-term phlebotomy is effective in promoting histological improvement above that spontaneously occurring in patients without virological response to interferonbased therapy, supporting the usefulness of this treatment in attenuating CHC progression when other therapies have failed.
